Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | Focusing on sex and hormones in MS prognosis

Burcu Zeydan, MD, Mayo Clinic, Rochester, MN, discusses the need to consider sex and hormones in addition to aging in a multiple sclerosis (MS) prognosis. During menopause, which can lower the level of anti-Müllerian hormones in the body, the symptoms of MS in patients are often exasperated. Patients can experience central nervous system (CNS) atrophy as well as higher rates of disability and neurodegeneration, which highlights the role of aging and hormonal loss in the severity of MS. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.